# Crafton Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/crafton-biotechnology

- Industry: Biotechnology
- Headquarters: Nagoya-shi, Japan
- Website: www.craftonbio.com
- Total disclosed funding: $0.7M
- Latest round: Seed (Jan 16, 2024)
- Investors on record: 1

## About

Based in Nagoya, Japan, and founded in 2022, SmileBack, LLC operates as a biopharmaceutical and drug discovery company. In January 2024, the firm raised JPY 100 million in seed funding led by investor Innovations and Future Creation. The firm as of January 2024, is led by its CEO, Seung Hak Kim.

The company specializes in mRNA drug discovery technology, providing domestically produced vaccines. Crafton's joint research initiatives involve collaboration with pharmaceutical companies, biotechs, and universities to address specific disease areas. Their diverse technology platform, including capping technology and sequence design, facilitates the development of mRNA drugs. The pipeline encompasses innovative mRNA-based therapeutics and next-generation preventive vaccines for infectious and rare diseases. Crafton Biotechnology also collaborates with universities, pharmaceutical companies, and other stakeholders to refine its platform technology, focusing on diseases with high medical needs.

The company plans to utilize the January 2024 funding to continue its research and add new medicines to its pipeline.

## Funding rounds

- Seed, Jan 16, 2024, $0.7M — Miraisozo Investments

## Investors

- Miraisozo Investments (https://capitalatlas.ai/funds/miraisozo-investments) — Seed